ArticleBritish journal of haematology2025
Secondary central nervous system lymphoma (SCNSL) in mantle cell lymphoma (MCL): Characteristics and risk factors in a Danish nationwide population-based study.
Article in British journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Secondary central nervous system lymphoma (SCNSL) in mantle cell lymphoma (MCL): Characteristics and risk factors in a Danish nationwide population-based study.British journal of haematology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Secondary central nervous system (CNS) lymphoma (SCNSL) in mantle cell lymphoma (MCL) is associated with dismal outcomes, and risk factors are not well documented. This population-based study reports the incidence of SCNSL, risk factors and survival. All patients diagnosed with MCL in Denmark in 2010-2022 without confirmed CNS involvement at diagnosis were included. Data were retrieved from the Danish National Lymphoma Registry and medical records. In total, 873 patients (median age 70 years) were included. The 10-year cumulative incidence of SCNSL was 3.8% (95% confidence interval [CI] 2.4-5.2). Risk factors for SCNSL were blastoid/pleomorphic MCL (hazard ratio [HR] 3.55, 95% CI 2.05-6.14), Ki67 ≥30% (HR 5.47, 95% CI 1.86-16.10) and elevated lactatedehydrogenase (HR 4.35, 95% CI 1.91-9.91). The 5-year cumulative incidence of SCNSL for patients with blastoid/pleomorphic MCL was 9.9% (95% CI 4.0-15.7). Patients with high CNS international prognostic index (CNS-IPI) had a high 1-year incidence of SCNSL of 5.8% (95% CI 1.6-10.0). Median progression-free survival and overall survival were 1.8 months (95% CI 1.3-4.7) and 2.4 months (95% CI 1.3-8.9). In conclusion, SCNSL of MCL is rare and associated with poor survival. Blastoid/pleomorphic subtype and high CNS-IPI identified patients at high risk of SCNSL for whom upfront screening for CNS involvement should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.